Telix Group inks deal with ININ to boost prostate imaging technology
Category: #health  By Pankaj Singh  Date: 2019-01-24
  • share
  • Twitter
  • Facebook
  • LinkedIn

Telix Group inks deal with ININ to boost prostate imaging technology

Telix Pharmaceuticals Limited, through its wholly-owned subsidiary Advanced Nuclear Medicine Ingredients SA (ANMI), has recently announced that it has entered into an agreement with Mexico’s Instituto Nacional de Investigaciones Nucleares (ININ) and completed the in-licensing of ININ’s 99mtechnetium-EDDA/HYNIC-Lys (NaI)-Urea-Glu (99mTc-iPSMA). Apparently, the product is an innovative clinical-stage radiopharmaceutical for prostate cancer imaging.

According to Telix, Single Photon Emission Computed Tomography, termed as SPECT, is widely deployed nuclear medicine imaging procedure, particularly for managing cancer, being an alternative to the Positron Emission Tomography or PET approach already being developed by ANMI. SPECT, even though similar to PET with regards to radioactive trace usage and gamma ray detection, is the dominant nuclear imaging modality in cancer management due to less availability of PET/CT worldwide.

Sources close to the matter informed that the team of ININ and its partners have been able to clinically evaluate 99mTc-iPSMA with SPECT/CT, the results of which show highly sensitive detection of lesions in prostate cancer. There is considerable commercial and clinical potential of the product for evaluating both primary disease and metastases in regions where extensive PET infrastructure is not present.

Reportedly, 99mTc-iPSMA has strong international patent protection in several commercial markets. 99mTc-iPSMA has been developed as result of world-class research performed by innovative ININ research group from the National Laboratory on Research and Development of Radiopharmaceuticals (LANIDER), sources mentioned. The group has substantial experience in the nuclear medicine field. 

Through scientific partnerships with the National Laboratories of the National Council of Science and Technology (CONACyT) and Mexican National Institute of Cancerology (INCan), LANIDER group maintains numerous international and national collaborations.

For the record, Telix is headquartered in Melbourne and has operations internationally in the U.S., Japan and EU. Telix’s license agreement with ININ represents a worldwide agreement and also includes a partnership for manufacturing the product.



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Incyte unveils positive results from Phase 2 ruxolitinib cream study
Incyte unveils positive results from Phase 2 ruxolitinib cream study
By Pankaj Singh

Vitiligo is a prominent skin diseases prevalent across the world that causes skin color loss. The disease is increasingly being taken as a serious issue by various pharmaceutical firms across the globe, who are continu...

Illumina inks a long-term NGS deal with Dutch company Qiagen
Illumina inks a long-term NGS deal with Dutch company Qiagen
By Pankaj Singh

The pharmaceutical industry is responsible for treating some of the most critical health issues. The sector produces, develops and markets drugs that could be beneficial to people on a larger scale. However, with ...

Graybug Vision commences Phase 2b Clinical study to target wet AMD
Graybug Vision commences Phase 2b Clinical study to target wet AMD
By Pankaj Singh

Macular degeneration is the leading cause of irreversible, serious vision loss that occurs when a section of the retina known as the macula is damaged. It is often observed that Age-Related Macular ...